Apo-Tiotropium Capsules Recall Due to Particle Size Issue
Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.
Apotex Inc. is recalling multiple lots of Apo-Tiotropium capsules because the particle size did not meet specifications.
What this Health Canada recall tells you, and what most readers miss
This notice was issued by Health Canada on August 3, 2026 and geographically references Canada. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, medication.
What Happened
Apotex Inc. is recalling Apo-Tiotropium capsules because the particle size did not meet the specifications in the affected lots.
Which Products Are Affected
The recall affects Apo-Tiotropium capsule (DIN 02550865), Tiotropium bromide monohydrate 18 mcg, in capsule form. Affected lot numbers are: LC87540, LC87541, LC87616, LC88196, LC88197, LC88316, LC88318, LC88319, LC89638, LC89639, LC89640, LC89641, LC89671, LC89681, LC89725, LC89783. The depth of recall is at the retailer level.
What You Should Do
Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada.
Why This Matters
The particle size specification issue may affect the quality of this prescription medication distributed by Apotex Inc.
Source
Original source: Health Canada Official Notice ↗
Related Product & Food Recalls
All Product & Food Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this Health Canada recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,161 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 3, 2026.
Frequently Asked Questions
Common questions about this Health Canada recall.